Navigation Links
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:10/22/2008

- MDV3100 Continues to Show Encouraging and Durable Anti-Tumor Activity and

Dose Escalation Continues - - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular

Targets and Cancer Therapeutics -

GENEVA and SAN FRANCISCO, Oct. 22 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new data from an ongoing Phase 1-2 clinical trial demonstrating that the Company's novel androgen receptor antagonist MDV3100 continues to show promising safety and efficacy results. The data showed encouraging and durable anti-tumor activity in the three expanded dose groups tested thus far, as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating tumor cell (CTC) changes, and time on treatment. MDV3100 has been generally well tolerated, with no reports of serious adverse events deemed related to MDV3100. Dose escalation in the trial is continuing.

"The tolerability and the anti-tumor activity seen with MDV3100 after six months of treatment remains encouraging," said Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center. "The trial continues to enroll rapidly and additional data will further clarify the potential of MDV3100 as a treatment option for patients with castration-resistant prostate cancer, who have a poor prognosis and for whom treatment options are limited."

MDV3100 Trial Design and Results to Date

The ongoing Phase 1-2 trial is an open-label U.S. dose-escalation study in prostate cancer patients who have failed standard hormonal therapies. To d
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
2. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Senior Management Promotions
9. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
10. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... While administrative claims and other ... for a relatively long period of time, there ... use of these ‘big data’ for comparisons of ... today’s powerful computer technology with the plethora of ... holds significant promise for identifying optimal interventions for ...
(Date:7/30/2014)... With the accelerated aging of ... expenditure as well as the improved medical care ... reagent industry has been developing quickly, especially in ... Chinese in vitro diagnostics market size reached RMB22.98 ... vitro diagnostic reagents. , Read complete report ...
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... --  Epic Sciences, Inc. ("Epic"), a private biotech ... and advance the treatment and management of cancer, announced ... as chairman of Epic,s board of directors. Mr. Lucier ... Invitrogen). Mr. Lucier joins Epic,s board of directors to ... analysis platform with special focus on the development of ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its ... before the opening of the U.S. financial,markets. The Company ... Internet,broadcast that will provide a business update and a ... at 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., ...
... Oct. 20 GeoVax Labs, Inc. (OTC,Bulletin Board: ... for diseases caused by HIV-1 (Human Immunodeficiency Virus),and ... both DNA and,MVA components of its AIDS vaccine ... use in the upcoming Phase 2a human clinical ...
... with Industry to Educate,Promote PRV Program-, WASHINGTON, ... today announced its support of the US Food ... Industry on Priority,Review Vouchers. The Priority Review Voucher ... the development of drugs and vaccines for,neglected tropical ...
Cached Biology Technology:SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 3FDA Issues Draft Guidance on Priority Review Vouchers 2
(Date:7/30/2014)... CHAMPAIGN, Ill. Scientists are searching through a massive ... more than 50 years ago, and the effort is ... world they inhabited. , When the collection is fully ... will be the largest unbiased Dominican amber collection in ... most striking discovery thus far is that of a ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
(Date:7/30/2014)... of the roughly 3,000 pieces is still in its ... results will be of major significance. "Amazingly often, we ... in Fushun amber that we found in Baltic amber," ... The Baltic amber comes from the Baltic Sea region, ... in finds are, e.g., the coastal regions of Mecklenburg, ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Chinese mosquitos on the Baltic Sea 2
... October 23, 2013 A promising technique for treating ... may lead to new treatments to prevent blindness, according to ... Jolla, California. The studies involved controlling the actions ... to be "junk" but are now known to fine-tune gene ...
... have found out which molecular mechanisms decide about the ... for the import of proteins into specific cell components, ... receptor remains active or is broken down after the ... regulation of the protein import into peroxisomes has been ...
... simply cannot do without lasers. We use them to print ... car components, survey roads, monitor our bloodstream, and even remove ... for Applied Solid State Physics IAF in Freiburg have developed ... a particular type of infrared laser forms the ...
Cached Biology News:New eye treatment effective in laboratory tests 2New eye treatment effective in laboratory tests 3New eye treatment effective in laboratory tests 4The yin and yang in the life of proteins 2Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3
... The PROTEAN II XL cell, wide format, is used ... x 20 cm gels and requires 1.2 L of ... unit and the 2.0 mm IPG conversion kit, which ... and includes 2 sets of IPG clamps, 2 sets ...
... been developed with the drug discovery process ... sensitivity and performance, Safire is the ideal ... development and high throughput screening. Safire is ... that offers a range of high speed ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: